Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.

Article Details

Citation
Copy to clipboard

Savelieva I, Graydon R, Camm AJ

Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.

Europace. 2014 Feb;16(2):162-73. doi: 10.1093/europace/eut274. Epub 2013 Oct 9.

PubMed ID
24108230 [ View in PubMed
]
Abstract

Pharmacological rhythm control (often including electrical or pharmacological cardioversion) is an integral part of therapy for atrial fibrillation (AF) worldwide. Antiarrhythmic drug strategies would be preferred in many patients provided effective and safe antiarrhythmic agents are available. Also, pharmacological cardioversion could be the preferred option if the limitations of currently available drugs, such as restriction to patients without structural heart disease (flecainide and propafenone), risk of torsade de pointes (ibutilide), and slow onset of action (amiodarone), were overcome. The intravenous formulation of vernakalant (Brinavess, Cardiome) has been approved for pharmacological cardioversion of recent-onset AF (

DrugBank Data that Cites this Article

Drugs